Owen, C.P. (2009) 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review. Anti-Cancer Agents in Medicinal Chemistry, 9(6), pp. 613-626. ISSN (print) 1871-5206Full text not available from this archive.
Prostate cancer is an age-related disease and a major cause of death in Western countries. A large proportion of prostate cancers have been found to be dependent on androgens for growth and various therapeutic approaches have aimed at either decreasing androgen levels or blocking their action. One method of decreasing androgen levels is through inhibition of enzymes involved in the biosynthetic pathway, for example, the P450 enzyme complex 17alpha-hydroxylase/C17,20-lyase (P450(17alpha)), which catalyses the conversion of pregnenolone and progesterone into the androgen precursors dehydroepiandrosterone and androstenedione respectively. A number of researchers have targeted this enzyme and have produced potent steroidal and non-steroidal inhibitors. This review looks at the various inhibitors that have been developed, focussing mainly on more recent inhibitors reported over the last ten years. Some mention is also given to structural requirements suggested to be important for potent activity.
|Uncontrolled Keywords:||lyase, hydroxylase, prostate cancer, enzyme, inhibitors, human cytochrome p450(17-alpha), imidazole-based inhibitors, hormone agonist therapy, steroid c-17(20) lyase, androgen synthesis, potential agents, in-vitro, p450 17, biochemical evaluation, c-17,c-20-lyase inhibitors|
|Faculty, School or Research Centre:||Faculty of Science (until 2011) > School of Pharmacy and Chemistry|
|Depositing User:||Automatic Import Agent|
|Date Deposited:||03 Feb 2010 14:26|
|Last Modified:||25 Nov 2011 11:58|
Actions (Repository Editors)
|Item Control Page|